Validation of ARIA (Allergic Rhinitis and its Impact on Asthma) classification in a pediatric population: the PEDRIAL study.
Allergic rhinitis (AR) is the commonest chronic disease in children. Allergic Rhinitis and its Impact on Asthma (ARIA) classification based on symptom duration (intermittent vs. persistent) and severity (mild vs. moderate/severe) has not been yet validated in children. Thus our objective was to validate ARIA classification in children, after determining the severity and duration of AR in a pediatric population, using ARIA definitions. Children aged 6-12 with a diagnosis of AR were included in an observational, cross-sectional, multicenter study. Patients were classified according to ARIA guidelines. AR symptoms were assessed using the Total Four Symptoms Score (T4SS). Severity was also evaluated by the patient using a visual analogue scale (VAS). Comparisons were made by means of a statistical analysis. One thousand two hundred and seventy-five children from 271 centers were included. Among them, 59.5% had intermittent and 40.5% persistent AR, while 60.7% seasonal and 39.3% perennial according to dated classification, with significant differences existing between one classification and another; 89.7% had moderate/severe rhinitis. Significantly higher T4SS and VAS scores were obtained in moderate/severe compared to mild AR. In our experience, the current ARIA classification can be considered a valid tool also in children from 6- to 12-yr old.
Servicio de Alergología, Hospital de Basurto, Avenida de Montevideo 18, Bilbao, Spain. ignacio.jaureguipresa@osakidetza.net
Ignacio
I
Jáuregui
Ignacio
I
Dávila
Joaquín
J
Sastre
Joan
J
Bartra
Alfonso
A
del Cuvillo
Marta
M
Ferrer
Javier
J
Montoro
Joaquim
J
Mullol
Xavier
X
Molina
Antonio
A
Valero
D000485:Allergens / Q000276:immunology; D000818:Animals; D001249:Asthma / Q000145:classification* / Q000453:epidemiology* / Q000276:immunology / Q000503:physiopathology; D002648:Child; D003430:Cross-Sectional Studies; D018450:Disease Progression; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D011058:Pollen / Q000009:adverse effects; D039981:Pyroglyphidae; D012720:Severity of Illness Index; D013030:Spain
D000485:Allergens